Skip to content
DataLookout
Start free
Menu

NCT04174196

A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma

StatusActive, Not Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 11 versions: 9 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Nov 19, 2025 to Nov 19, 2026v11
  2. Primary and study completion dates: Nov 19, 2024 to Nov 19, 2025v9
  3. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 20 to confirmed 21
    • Site details revised at 7 of 7 sites
    v7
  4. Primary and study completion dates: Nov 19, 2023 to Nov 19, 2024
    • Study sites revised (7)
    v6
  5. Eligibility criteria shortened, about 5 wordsv5
Show 3 earlier versionsHide 3 earlier versions
  1. Primary and study completion dates: Nov 19, 2021 to Nov 19, 2023v4
  2. Eligibility criteria expanded, about 70 wordsv3
  3. Eligibility criteria expanded, about 17 wordsv2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Measure Complete Response
Timeframe: At the end of Cycle 6 (each cycle is 28 days)

Arms and interventions

Participants with PlasmacytomaExperimental

Participants will have solitary bone plasmacytoma with minimal marrow involvement and participants with relapsed multiple myeloma with plasmacytomas

Drugs: CC-486, Lenalidomide

Radiation: Radiation Therapy

Sites

7 sites in 1 country